Beam Therapeutics (BEAM) Citigroup’s Biopharma Back to School Summit 2026 summary

Pipeline progress and clinical updates

• Advancing a broad pipeline using base editing and next-gen CRISPR 2.0, with mature internal manufacturing and delivery capabilities.

• Risto-cel (sickle cell) is fully enrolled in the BEACON trial, with a BLA filing expected around year-end.

• BEAM-302 for AATD is in a pivotal cohort, with strong enrollment and durable, protective AAT levels shown in new data.

• BEAM-301 (GSD1a) will have first-in-human data this year; BEAM-304 (PKU) has an open IND and will begin screening patients by year-end.

• Platform enables rapid expansion to additional indications using the same delivery and editing technologies.

Competitive positioning and product differentiation

• BEAM-302 is two years ahead of competitors in pivotal trials for AATD, with a clear first-in-class advantage.

• Achieves protective AAT levels and significant Z protein reduction, addressing both liver toxicity and systemic inflammation.

• Clinical differentiation above the protective threshold is limited; focus is on quality and durability of response.

• Strong physician and patient enthusiasm, with high enrollability and demand at trial sites.

Regulatory and commercial strategy

• Aligned with FDA on accelerated approval for AATD, leveraging robust biomarker data and RMAT designation.

• Confirmatory trial will focus on functional outcomes; regulatory engagement has been proactive and supportive.

• Initial commercial launch for AATD will target 10,000–15,000 diagnosed ZZ patients via specialist centers, with long-term plans to expand diagnosis and access.

• Sickle cell launch preparations include new commercial leadership, operational ramp-up, and leveraging learnings from prior market entrants.